Research Review · MCAS & histamine · Insulin resistance & blood sugar
The Histamine–Insulin Connection: Biological Crosstalk and the Limits of Current Evidence
A narrative review of histamine receptor signaling, insulin secretion, glucose metabolism, adipose mast cells and the limits of evidence for a clinical histamine–insulin cycle.
- Author
- By Sevanie Romoda, MD
- Published
- Updated
- 14 min read
Short answer
Histamine and insulin pathways interact biologically, but current evidence does not establish that histamine intolerance or MCAS causes insulin resistance, that insulin resistance worsens histamine-related disease, or that a clinical histamine–insulin feedback loop exists in humans.
Evidence summary
- Evidence strength
- Emerging
- Direct evidence
- Insufficient
- Last evidence review
Research Review · Narrative Review
Sevanie Romoda, MD Independent Researcher; Founder, Signal Repair
Abstract
### Background Histamine is an immune mediator and neurotransmitter with actions extending well beyond allergy. Insulin is central to glucose and lipid homeostasis. Experimental studies indicate that histamine-receptor signaling can alter pancreatic insulin secretion, exercise-associated insulin sensitivity, energy homeostasis, and inflammatory activity in adipose tissue. These observations have led to broader claims that histamine-related disorders may drive insulin resistance, or that insulin resistance may worsen histamine-related illness. Those clinical claims remain insufficiently tested.
### Objective To review evidence for biological interaction between histamine and insulin signaling, distinguish mechanistic and preclinical findings from human clinical evidence, examine contradictory observations, and define research priorities required before a causal clinical feedback model can be supported.
### Methods This narrative review draws on selected mechanistic, animal, human observational, interventional, guideline, and review literature identified through focused searches of PubMed, PubMed Central, and publisher databases. Search concepts included histamine receptors, pancreatic beta cells, insulin secretion, insulin sensitivity, glucose metabolism, adipose mast cells, metabolic syndrome, histamine intolerance, mast cell activation syndrome, and antihistamines. The review was designed to characterize the state and limits of the evidence rather than to provide an exhaustive or systematic synthesis.
### Results Histamine receptors are expressed in pancreatic beta-cell models, and receptor-specific experiments show that histaminergic signaling can alter glucose-stimulated insulin secretion. Older human experimental data also demonstrate that exogenous histamine can stimulate insulin secretion through an H2-receptor-sensitive pathway. In mice, deletion of H1 or H2 histamine receptors alters glucose and lipid metabolism, whereas human exercise experiments suggest that H1/H2 signaling contributes to the increase in insulin sensitivity after exercise. Human adipose-tissue studies are inconsistent: some report greater mast-cell abundance associated with metabolic syndrome, inflammation, fibrosis, or insulin-resistance markers, whereas others find mast-cell accumulation independent of systemic insulin resistance or even lower mast-cell abundance in some metabolically adverse obesity phenotypes. A 2026 systematic review of H1 antihistamines identified heterogeneous experimental and clinical findings, with several studies suggesting improved glucose metabolism rather than a uniformly harmful effect of histamine blockade. Evidence concerning suspected histamine intolerance is similarly uncertain; placebo-controlled challenge studies frequently fail to confirm the diagnosis, and serum diamine oxidase has insufficient specificity as a stand-alone biomarker.
### Conclusions Histamine–insulin interaction is biologically plausible and supported by receptor-level, cellular, animal, and limited human physiological evidence. However, the direction of effect varies by receptor, tissue, physiologic context, and experimental model. Current evidence does not establish that histamine intolerance or mast cell activation syndrome causes insulin resistance, that insulin resistance causes or worsens histamine intolerance, or that a self-reinforcing clinical “histamine–insulin cycle” exists in humans. Prospective human studies using validated mast-cell mediator measurements, rigorous metabolic phenotyping, and predefined clinical groups are required before such a model can be considered established or used to guide treatment.
Keywords: histamine; insulin; glucose metabolism; insulin secretion; mast cells; insulin resistance; metabolic syndrome; histamine intolerance; mast cell activation syndrome
Introduction
Histamine is most familiar as a mediator of allergic reactions, but its physiology is substantially broader. It acts through four receptor subtypes—H1, H2, H3, and H4—that differ in tissue distribution, intracellular signaling, and functional effects. Histamine participates in vascular tone, gastric acid secretion, immune signaling, neurotransmission, feeding behavior, energy homeostasis, and inflammatory responses.
Insulin is likewise a systems-level hormone. Secreted by pancreatic beta cells in response to nutrients and other signals, it regulates hepatic glucose production, skeletal-muscle glucose uptake, adipose-tissue lipolysis, lipid storage, and multiple anabolic pathways.
Because histamine receptors are expressed in metabolic tissues and because immune and metabolic systems communicate continuously, interaction between histaminergic signaling and insulin physiology is biologically plausible.
The critical scientific issue is not whether the two systems can interact. They can.
The unresolved question is whether available evidence supports a clinically important, bidirectional disease mechanism in humans.
Evidence that a histamine receptor alters insulin secretion in a cell line does not establish that a patient with food-associated symptoms has insulin resistance. An association between mast cells and adipose inflammation does not establish that histamine caused the metabolic abnormality. Likewise, altered glucose metabolism does not demonstrate impaired histamine degradation or mast-cell activation.
This distinction is especially important because terms such as "histamine intolerance," mast cell activation syndrome (MCAS), insulin resistance, and metabolic syndrome are often combined in public discussion as though they describe one unified pathway.
They do not.
This review examines the evidence for histamine–insulin crosstalk, the contradictory findings that constrain interpretation, and the studies that would be needed to establish a clinically meaningful feedback model.
Histamine Receptors and Pancreatic Beta-Cell Function
### H3-receptor signaling
Nakamura and colleagues demonstrated histamine H3-receptor expression in pancreatic beta cells using mouse islets, a mouse beta-cell line, and immunohistochemical evidence in human beta cells. In functional MIN6-cell experiments, an H3-receptor agonist inhibited glucose-induced insulin secretion, whereas an H3 inverse agonist facilitated it.
These findings provide direct mechanistic evidence that histaminergic signaling can modify beta-cell function.
They do not establish the magnitude or direction of this effect in living humans under ordinary physiological conditions.
The distinction matters because receptor activation in an isolated beta-cell model is different from dietary histamine exposure, mast-cell mediator release, or a clinical syndrome.
### H1 and H2 receptors in beta-cell models
Nagata and colleagues examined several monoamine-receptor systems in a hamster pancreatic beta-cell line while studying olanzapine-associated impairment of insulin secretion. H1-receptor stimulation increased insulin secretion in that model, whereas H1 blockade reduced it. H2-receptor stimulation produced a different effect.
The study reinforces a recurring theme: histamine cannot be treated as a single metabolic signal.
Different receptor subtypes can produce different—and potentially opposing—effects.
Because olanzapine interacts with multiple receptor systems and because the experiment used an immortalized beta-cell model, these findings should be interpreted mechanistically rather than clinically.
Direct Human Evidence That Histamine Can Affect Insulin Secretion
Human evidence is limited but not absent.
In a small randomized double-blind study published in 1980, Grund and colleagues administered intravenous histamine to six fasting men. Histamine increased circulating insulin without significantly altering glucose, and pretreatment with the H2-receptor antagonist cimetidine markedly inhibited the insulin response.
This experiment shows that histamine is capable of influencing insulin secretion in humans under controlled pharmacologic conditions.
It does not show that ordinary dietary histamine exposure produces the same effect.
It also does not demonstrate chronic insulin resistance.
Acute insulin secretion and chronic insulin resistance are distinct physiological questions.
Histamine Receptors and Whole-Body Glucose Metabolism
### Animal receptor-knockout studies
Wang, Tanimoto and colleagues examined mice lacking H1 or H2 receptors. H1-receptor knockout mice showed mild insulin resistance, whereas H2-receptor knockout mice showed more substantial insulin resistance and glucose intolerance. Disturbances in lipid metabolism and liver pathology were also observed.
These results strongly support a role for histamine-receptor pathways in metabolic regulation in mice.
However, lifelong genetic deletion of a receptor is a profound experimental manipulation.
It should not be treated as equivalent to transient histamine elevation, food-associated histamine symptoms, antihistamine use, or MCAS in a human patient.
### Histamine signaling after exercise
A small human experiment by Pellinger and colleagues provides particularly useful physiological evidence.
Twenty healthy young adults participated in randomized exercise and sham conditions. Combined H1- and H2-receptor blockade reduced the improvement in insulin sensitivity normally observed after exercise by approximately 25%, while receptor blockade did not produce the same effect in non-exercise trials.
The finding suggests that histamine-mediated vascular or metabolic signaling contributes to post-exercise glucose regulation.
It also illustrates why the claim "histamine worsens insulin resistance" is too simplistic.
In this setting, histamine-receptor signaling appeared to support insulin sensitivity.
Central Histamine and Energy Homeostasis
Histaminergic signaling also influences metabolism indirectly through the central nervous system.
Hypothalamic histamine participates in appetite regulation, thermogenesis, circadian physiology, and energy expenditure. H1 and H3 receptors can exert different effects on feeding behavior, and disruption of central histaminergic pathways in animal models can alter body weight and energy balance.
These mechanisms may be relevant to long-term metabolic phenotype.
But central energy regulation is conceptually different from food-triggered histamine symptoms or mast-cell activation.
The presence of multiple metabolic roles for histamine makes a single-direction "high histamine equals insulin resistance" model increasingly difficult to defend.
Mast Cells, Adipose Tissue, and Metabolic Dysfunction
Mast cells release histamine, but they also release tryptase, chymase, prostaglandins, leukotrienes, cytokines, and other mediators.
Therefore, a study linking mast cells to metabolic disease is not automatically evidence that histamine itself caused the metabolic effect.
### Preclinical evidence
A widely cited 2009 Nature Medicine study reported that mast-cell deficiency or pharmacologic stabilization reduced diet-induced obesity and improved glucose homeostasis in mice. The work provided important evidence that mast cells can participate in metabolic inflammation in experimental models.
However, mouse mast-cell deficiency models have biological limitations, and pharmacologic mast-cell stabilizers may have effects beyond a single mediator pathway.
Translation to human insulin resistance therefore requires independent clinical evidence.
### Human adipose-tissue observations
Divoux and colleagues found mast cells in human adipose tissue and reported associations with adipose inflammation, fibrosis, obesity, and diabetes-related features.
Gurung and colleagues subsequently compared subcutaneous adipose tissue from 19 participants with metabolic syndrome and 15 controls. Mast-cell abundance was higher in the metabolic-syndrome group and correlated with HOMA-IR, adipose-tissue insulin resistance, triglycerides, inflammatory markers, fibrosis, and other metabolic measures.
These findings support an association between adipose mast cells and metabolically adverse tissue environments.
But the sample sizes were small and observational.
Association cannot establish directionality.
### Contradictory human findings
Other human data complicate a simple causal model.
Einwallner and colleagues found increased mast-cell-related signals in adipose tissue from people with obesity, but the accumulation was independent of systemic insulin resistance. Their work suggested a role in local adipose inflammation rather than a primary causal role in systemic insulin resistance.
Additional human obesity studies have reported that higher adipose mast-cell accumulation can associate with comparatively favorable metabolic phenotypes, and one 2021 study reported fewer adipose mast cells in participants with obesity and type 2 diabetes than in those with obesity without diabetes.
These findings do not establish that mast cells are metabolically protective.
They demonstrate that human adipose mast-cell biology is more heterogeneous than a simple "more mast cells equals more insulin resistance" model.
Histamine Is Only One Mast-Cell Mediator
This distinction deserves emphasis.
Mast cells can produce a broad range of biologically active substances.
If mast-cell abundance correlates with fibrosis or insulin resistance, the observation does not identify histamine as the responsible molecule.
Potential mechanisms could involve:
- cytokines
- proteases
- prostaglandins
- leukotrienes
- interactions with macrophages
- angiogenesis
- extracellular-matrix remodeling
- histamine
- combinations of these pathways
A clinically meaningful histamine–insulin model therefore requires mediator-specific evidence, not merely evidence that mast cells are present in metabolically active tissue.
Histamine Intolerance: A Major Translational Limitation
Any clinical theory connecting "histamine intolerance" to insulin resistance must confront a basic problem:
histamine intolerance itself lacks a universally accepted diagnostic standard.
A 2021 multidisciplinary guideline concluded that evidence linking ingested histamine to reproducible symptoms is limited and contradictory and that serum diamine oxidase measurements are inconclusive for routine diagnosis.
A 2023 placebo-controlled histamine-challenge study evaluated 59 people with suspected histamine intolerance. Histamine intolerance was excluded in the majority, placebo responses were frequent, and serum DAO lacked sufficient specificity to function as a stand-alone diagnostic test.
This does not demonstrate that dietary histamine never causes symptoms.
It shows that self-reported histamine intolerance is not equivalent to a validated biological phenotype.
That matters greatly for future metabolic studies.
If the exposure group itself is poorly defined, causal conclusions about insulin resistance become unreliable.
Mast Cell Activation Syndrome Is a Separate Clinical Entity
MCAS should not be used interchangeably with histamine intolerance.
Current clinical criteria require a compatible pattern of recurrent systemic symptoms, objective biochemical evidence of mast-cell mediator release, and clinical response to appropriate mediator-targeted therapy, while alternative diagnoses are considered.
Food reactions, flushing, diarrhea, palpitations, or metabolic abnormalities alone do not establish MCAS.
Therefore, studies attempting to evaluate a histamine–insulin relationship should distinguish at minimum:
- confirmed MCAS
- suspected food-associated histamine reactions
- IgE-mediated allergy
- metabolic syndrome
- obesity
- type 2 diabetes
- healthy control populations
Combining these groups would obscure rather than clarify the biology.
Antihistamines and Glucose Metabolism: Evidence Against a Simple Model
A 2026 systematic review of H1-receptor antagonists identified 17 eligible in vivo, in vitro, clinical, and in-silico studies.
Many included reports suggested improvements in glucose tolerance, insulin sensitivity, or insulin secretion with antihistamine exposure, although the literature was heterogeneous and the authors emphasized the need for better human trials before clinical use could be recommended.
This finding is important because a simple clinical model might predict that blocking histamine should consistently worsen metabolic regulation.
The literature does not show that.
At the same time, older epidemiologic data have associated prescription H1-antihistamine use with higher body weight, waist circumference, and insulin levels, although such observational studies are vulnerable to confounding and cannot establish causation.
Together these findings reinforce receptor-, drug-, tissue-, and context-specific effects.
They do not support using antihistamines as treatments for insulin resistance.
They also do not support claiming that antihistamines inevitably worsen insulin sensitivity.
The Broader Histamine–Metabolic Syndrome Literature
A 2024 review by Wang and colleagues summarized histamine signaling across obesity, insulin resistance, dyslipidemia, hypertension, and other features of metabolic syndrome.
The review supports histaminergic pathways as legitimate metabolic research targets.
But much of the mechanistic foundation remains preclinical.
Similarly, earlier reviews of histamine in diabetes have emphasized renewed interest in the field while noting that independent human evidence remains comparatively sparse.
The correct interpretation is therefore:
histamine participates in metabolic biology.
That statement is considerably stronger than saying:
a histamine-related clinical disorder causes insulin resistance.
The first is supported.
The second remains unproven.
Is There Evidence for a Bidirectional Histamine–Insulin Cycle?
At present, no sufficiently validated human evidence establishes a self-reinforcing clinical feedback loop in which:
1. histamine intolerance or MCAS causes insulin resistance, 2. insulin resistance then causes impaired histamine degradation or further mast-cell activation, 3. that process perpetuates the clinical syndrome.
Individual components of such a hypothesis may be biologically conceivable.
For example:
- histamine receptors can affect insulin secretion,
- metabolic inflammation can involve mast cells,
- adipose tissue is immunologically active,
- glucose, insulin, and lipids can influence immune-cell function.
But biological plausibility is not the same as demonstration of the complete pathway.
The current literature does not establish the sequence, directionality, magnitude, or clinical prevalence required to call this a syndrome, cycle, or treatment target.
Clinical Implications
The current evidence does not justify recommending:
- antihistamines as treatment for insulin resistance,
- DAO supplementation as treatment for insulin resistance,
- low-histamine diets as metabolic therapy,
- insulin-lowering strategies as established treatment for MCAS,
- insulin-lowering strategies as established treatment for suspected histamine intolerance.
Patients can simultaneously have metabolic dysfunction and histamine-related symptoms.
Each condition should be evaluated on its own clinical evidence.
A person with suspected mast-cell disease should receive appropriate diagnostic assessment.
A person with insulin resistance or diabetes should receive evidence-based metabolic evaluation and treatment.
Future evidence may identify clinically meaningful overlap.
Current evidence does not justify substituting an unvalidated unifying model for established diagnostic pathways.
Strengths and Limitations of the Current Evidence
The literature has several strengths.
There is direct receptor-level evidence.
There are animal models demonstrating metabolic effects.
There are human physiological experiments showing that histamine manipulation can affect insulin secretion and post-exercise insulin sensitivity.
There are human adipose-tissue studies demonstrating immunometabolic associations.
But the limitations are substantial.
First, much of the mechanistic evidence is preclinical.
Second, receptor effects differ by receptor subtype and tissue.
Third, many human studies are small.
Fourth, mast-cell studies cannot isolate histamine from other mast-cell mediators.
Fifth, histamine intolerance lacks a standardized biomarker-defined phenotype.
Sixth, observational adipose studies cannot establish temporal direction.
Seventh, metabolic outcomes such as fasting glucose, HOMA-IR, postprandial glucose, insulin secretion, clamp-derived insulin sensitivity, and diabetes are not interchangeable endpoints.
Finally, there are no robust prospective clinical studies directly testing the proposed bidirectional histamine–insulin feedback model in a well-defined patient population.
Research Priorities
A rigorous research program should move beyond broad correlations.
### 1. Define the clinical phenotypes
Future studies should separately recruit people with:
- consensus-confirmed MCAS
- reproducible food-associated histamine reactions established using controlled challenge where feasible
- metabolic syndrome
- insulin resistance defined using validated metabolic methodology
- type 2 diabetes
- matched healthy controls
### 2. Measure mast-cell mediators and metabolic physiology together
Studies should pair appropriate mast-cell mediator measurements with metabolic outcomes such as:
- fasting insulin and glucose
- oral glucose tolerance testing
- continuous glucose monitoring where relevant
- standardized meal challenges
- insulin-sensitivity measurements
- lipid phenotyping
### 3. Establish temporality
Prospective studies are needed to determine whether changes in mediator activity precede changes in insulin sensitivity or vice versa.
Cross-sectional correlation cannot answer this question.
### 4. Separate receptor pathways
H1, H2, H3, and H4 receptors should not be treated as one exposure.
Their effects differ by tissue and signaling pathway.
### 5. Control major confounders
Studies should account for:
- adiposity
- visceral fat
- medications
- antihistamine use
- diet
- exercise
- sleep
- sex hormones
- alcohol
- inflammatory disease
- allergy
- infection
- metabolic medications
### 6. Test interventions only after phenotype definition
If observational work identifies a reproducible relationship, randomized studies could then examine interventions such as receptor-specific antagonism, dietary histamine modification, or metabolic therapies.
Intervention should follow mechanism—not substitute for establishing it.
Discussion
The existing evidence supports histamine–insulin crosstalk at multiple biological levels.
Histamine receptors can modify pancreatic insulin secretion.
Histamine signaling can participate in exercise-related insulin sensitivity.
Histamine receptors influence energy and lipid metabolism in animal models.
Mast cells are present in metabolically active adipose tissue and can participate in inflammatory remodeling.
Yet none of these findings establishes a unified clinical histamine–insulin cycle.
Indeed, several findings actively resist such simplification.
Receptor effects can oppose one another.
Histamine signaling may support insulin sensitivity in one physiological context.
Human mast-cell studies are inconsistent.
Antihistamine studies do not show one uniform metabolic direction.
And suspected histamine intolerance is itself difficult to define reproducibly.
The most defensible conclusion is therefore not that the proposed connection is false.
It is that the connection is biologically plausible, clinically unproven, and scientifically testable.
That is a useful position because it converts a broad clinical hypothesis into a research agenda.
Conclusion
Experimental and limited human studies demonstrate meaningful interaction between histaminergic pathways and metabolic regulation.
Histamine receptors can influence insulin secretion, glucose handling, energy homeostasis, and post-exercise insulin sensitivity. Mast cells may participate in adipose inflammation and metabolic remodeling.
However, these findings are receptor-specific, tissue-specific, context-dependent, and sometimes contradictory.
At present, available evidence does not establish that histamine intolerance causes insulin resistance, that MCAS causes insulin resistance, that insulin resistance causes histamine intolerance or MCAS, or that a self-reinforcing clinical histamine–insulin cycle exists in humans.
The histamine–insulin connection should therefore be treated as a legitimate research hypothesis rather than an established diagnostic or therapeutic framework.
Its clinical significance will require prospective human studies using carefully defined phenotypes, validated mast-cell mediator measurements, rigorous metabolic assessment, and designs capable of establishing temporality and causation.
Funding
No external funding was received for this work.
Conflict of Interest
Sevanie Romoda created the Insulin Signal Repair Protocol and is the founder of Signal Repair, a commercial health-education and personalized nutrition platform relevant to the subject of this review. This relationship is disclosed because the article examines biological mechanisms related to the platform's research and educational focus.
Review Type
Narrative review. This article is not a systematic review and does not claim an exhaustive literature search.
Evidence & references
- Limited evidenceThe expression and function of histamine H3 receptors in pancreatic beta cells. (opens in new tab)
Nakamura T, Yoshikawa T, Noguchi N, et al.. Br J Pharmacol. 2014;171(1):171-185. 2014 · PMID 24117016
Mouse islets, MIN6 cells and human beta-cell immunohistochemistry; mechanistic.
- Limited evidenceBlockade of multiple monoamines receptors reduce insulin secretion from pancreatic β-cells. (opens in new tab)
Nagata M, Yokooji T, Nakai T, et al.. Sci Rep. 2019;9(1):16438. 2019 · PMID 31712714
Beta-cell line model; mechanistic.
- Limited evidenceCimetidine blockade of histamine-induced insulin secretion. (opens in new tab)
Grund VR, Martino R, Hunninghake DB. Clin Pharmacol Ther. 1980;28(3):392-397. 1980 · PMID 6996897
Small human pharmacologic experiment (n=6); acute secretion only.
- Limited evidenceHistamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice. (opens in new tab)
Wang KY, Tanimoto A, Yamada S, et al.. Am J Pathol. 2010;177(2):713-723. 2010 · PMID 20566747
Receptor-knockout mouse study.
- Emerging evidenceEffect of H1- and H2-histamine receptor blockade on postexercise insulin sensitivity. (opens in new tab)
Pellinger TK, Dumke BR, Halliwill JR. Physiol Rep. 2013;1(2):e00033. 2013 · PMID 24303118
Small randomized human physiology experiment (n=20).
- Limited evidenceGenetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. (opens in new tab)
Liu J, Divoux A, Sun J, et al.. Nat Med. 2009;15(8):940-945. 2009 · PMID 19633655
Mouse model; mast-cell deficiency models have limitations.
- Limited evidenceMast cells in human adipose tissue: link with morbid obesity, inflammatory status, and diabetes. (opens in new tab)
Divoux A, Moutel S, Poitou C, et al.. J Clin Endocrinol Metab. 2012;97(9):E1677-E1685. 2012 · PMID 22745246
Human observational adipose-tissue study.
- Limited evidenceIncreased mast cell abundance in adipose tissue of metabolic syndrome: relevance to the proinflammatory state and increased adipose tissue fibrosis. (opens in new tab)
Gurung P, Moussa K, Adams-Huet B, Devaraj S, Jialal I. Am J Physiol Endocrinol Metab. 2019;316(3):E504-E509. 2019 · PMID 30620639
Small cross-sectional study (19 vs 15).
- Limited evidenceMast cells are not associated with systemic insulin resistance. (opens in new tab)
Einwallner E, Kiefer FW, Di Caro G, et al.. Eur J Clin Invest. 2016;46(11):911-919. 2016 · PMID 27600500
Contradictory human finding.
- Limited evidenceIn Patients With Obesity, the Number of Adipose Tissue Mast Cells Is Significantly Lower in Subjects With Type 2 Diabetes. (opens in new tab)
Lopez-Perez D, Redruello-Romero A, Garcia-Rubio J, et al.. Front Immunol. 2021;12:664576. 2021 · PMID 34093556
Contradictory human finding.
- Moderate evidenceGuideline on management of suspected adverse reactions to ingested histamine: Guideline of the DGAKI, GPA, AeDA, SGAI and ÖGAI. (opens in new tab)
Reese I, Ballmer-Weber B, Beyer K, et al.. Allergol Select. 2021;5:305-314. 2021 · PMID 34651098
Multisociety guideline (German, Swiss and Austrian allergy societies); society names abbreviated.
- Moderate evidencePlacebo-Controlled Histamine Challenge Disproves Suspicion of Histamine Intolerance. (opens in new tab)
Bent RK, Kugler C, Faihs V, Darsow U, Biedermann T, Brockow K. J Allergy Clin Immunol Pract. 2023;11(12):3724-3731.e11. 2023 · PMID 37648152
Placebo-controlled challenge (n=59).
- Moderate evidenceDiagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026. (opens in new tab)
Akin C, Gülen T, Castells MC, Oude Elberink HNG, Valent P. J Allergy Clin Immunol Pract. 2026;14(1):19-28. 2026 · PMID 41285202
Current clinical criteria for MCAS.
- Emerging evidenceTargeting histamine in metabolic syndrome: Insights and therapeutic potential. (opens in new tab)
Wang Y, Fang F, Liu X. Life Sci. 2024;358:123172. 2024 · PMID 39461668
Narrative review; largely preclinical basis.
- Emerging evidenceHistamine in diabetes: Is it time to reconsider? (opens in new tab)
Pini A, Obara I, Battell E, Chazot PL, Rosa AC. Pharmacol Res. 2016;111:316-324. 2016 · PMID 27343700
Narrative review.
- Emerging evidenceAntidiabetic Properties of Histamine H1 Receptor Antagonists: A Systematic Review. (opens in new tab)
Radzikowski M, Maciejczyk M. Antioxidants (Basel). 2026;15(9):1098. 2026 · PMID 42792137
Heterogeneous mixed in vivo/in vitro/clinical/in-silico studies.
- Limited evidenceAssociation of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. (opens in new tab)
Ratliff JC, Barber JA, Palmese LB, Reutenauer EL, Tek C. Obesity (Silver Spring). 2010;18(12):2398-2400. 2010 · PMID 20706200
Observational NHANES association; confounding possible.
Signal Journal is Signal Repair's evidence-focused publication examining what research demonstrates, suggests, and has not yet established about food and individual response. Articles are general education, not individual medical advice; an association is not proof of cause, and insufficient evidence does not mean something has been shown to be false.
Signal Repair™ content is educational and is being developed alongside a self-tracking tool. It does not diagnose, treat, cure, or prevent disease and is not a substitute for professional medical care. Talk with a qualified clinician before changing your diet or treatment.
Want a tool that learns your patterns?
Join Signal Repair™ early access